Pancreatic cancer remains a devastating disease and> 96% of patients with pancreatic
cancer do not survive for more than 5 years. Gemcitabine (2'-deoxy-2'-difluoro-deoxycytidine: …

LY294002 and wortmannin are chemical compounds that act as potent inhibitors of
phosphoinositide 3-kinases (PI3Ks). Both of them are generally used to inhibit cell proliferation as …

BACKGROUND: Hepatocellular carcinoma (HCC) originating in the caudate lobe is rare, and
the treatment for this type of carcinoma is difficult because of its unique anatomic location. …

Family members of the connective tissue growth factor, cysteine-rich 61, nephroblastoma
over-expressed gene (CCN) encode cysteine-rich secreted proteins with roles in human …

The prognosis of patients with pancreatic cancer is very poor because of late diagnosis and
the lack of response to various therapies. Pancreatic cancer is generally resistant to …

Slingshot-1L (SSH1L), a cofilin-phosphatase, plays a role in actin dynamics and cell migration
by reactivating cofilin-1. However, the expression of SSH1L in malignant diseases is …

Gemcitabine is a new standard chemotherapeutic agent used in the treatment of pancreatic
cancer, but the mechanisms of gemcitabine sensitivity are still controversial. In our study to …

Background: Gemcitabine (2′-deoxy-2′-difluorodeoxycytidine: Gemzar) (GEM) appears
to be the only effective anticancer drug for pancreatic cancer, but it has little impact on …

Background. The long-term prognosis after resection for patients with hepatocellular carcinoma
is still unsatisfactory because of the high recurrence rate. The survival of patients with …

Background: Our previous proteomic study demonstrated that expression of heat shock
protein 27 (HSP27) is upregulated in gemcitabine (GEM)-resistant pancreatic cancer cells and …